Australian scientists have used Artificial Intelligence (AI) to generate a ready-to-use biological protein that can kill antibiotic resistant bacteria like E. coli.

Antibiotics are one of the greatest triumphs in the history of medical science—but these lifesaving tools have a dark side.

Antibiotic resistance poses a growing global health crisis, and researchers are turning to evolutionary biology for solutions. A groundbreaking study has mapped the evolutionary history of Escherichia ...

Credit: Saiful52/Shutterstock. WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins and plasmid DNA (pDNA). The worldwide market ...

The antiplasmid activity of the in-house synthesized compounds was evaluated against an E. coli tolC mutant harboring the pScreening synthetic plasmid as we previously described using dual plasmid and ...

Tomoiaga, D., Bubnell, J., Herndon, L. and Feinstein, P. (2022) High Rates of Plasmid Cotransformation in E. coli Overturn the Clonality Myth and Reveal Colony Development. Scientific Reports, 12, ...

Asahi Kasei Medical's subsidiary Bionova Scientific has plans to launch a plasmid DNA business and for this it will develop a new facility in Texas, USA. The unit is scheduled to begin in the first ...

An integrated approach for modelling, monitoring and control the plasmid bioproduction in Escherichia coli cultures is presented. In a first stage, by the implementation of a kinetic model for E. coli ...

The E. coli plasmid (circular DNA) used for display contains a gene that expresses green fluorescent protein (GFP), and when this GFP is expressed, E. coli emits fluorescence.

An integrated approach for modelling, monitoring and control the plasmid bioproduction in Escherichia coli cultures is presented. In a first stage, by the implementation of a kinetic model for E. coli ...

Carbapenem resistance in Norway is low in clinics, with no VIM-1-carrying E coli detected in 2021. 5 However, the emergence of an IncHI2 plasmid carrying VIM-1 carbapenemase with multiple ARGs and ...